The content on this site is intended for healthcare professionals only
Dr Jonathan Lancaster speaks with ecancer at SABCS 2017 about an updated genomic screening tool for life-time breast cancer risk.
He outlines how the test assesses 86 single nucleotide polymorphisms linked to cancer aetiology to provide clinically validated likelihood of disease.
Dr Lancaster considers the potential psychological impact for women with a family history of breast cancer, and notes that this tool is a modified function of existing myRisk assays, already in clinical use, so can be introduced to practice quickly and at no cost.
Insights into germline genetic screening of breast cancer patients
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Advancing breast cancer treatment in Uganda by improving molecular testing
Somatic mutation profile of breast cancer in Uganda
Low-cost detection and treatment strategies for breast cancer patients in LMICs
Choosing wisely in breast cancer
Choosing Wisely in radiology Tanzania
